Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABY-029 in recurrent glioma
NCT02901925Phase 1Completed
- Sponsor
- Dartmouth Health
- Start
- Feb 2017
- Primary completion
- Jun 2021
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of ABY-029 in glioma (3 arms), sponsored by Dartmouth Health. Primary endpoint: Fluorescence Signal Detection. Started Feb 2017; status: completed.
02
Drugs
ABY-029
03
Conditions
glioma
Beyond the preview
Go deeper on NCT02901925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02901925.